ResApp Health Ltd
(ASX:RAP) has announced positive results from its first preliminary adult clinical study.
ResApp has trialled its cough-based diagnostic technology on 143 adult patients in Perth.
The company says its in-development smartphone app can tell the difference between patients suffering from asthma, pneumonia and chronic obstructive pulmonary disease. ResApp also says its app can distinguish between those conditions with at least 92% accuracy (depending on the condition).
The company will conduct further trials on adult patients in Brisbane.
ResApp reported a net loss of $1.5 million at 31 December 2015.
